Fluvoxamine versus other anti‐depressive agents for depression
No strong evidence was found to suggest that fluvoxamine was superior or inferior to other antidepressants in the acute phase treatment of depression.
Fluvoxamine is one of the oldest selective serotonin reuptake inhibitors (SSRIs) and is prescribed to patients with major depression in many countries. This review evaluates the effectiveness, tolerability and side effect profile of fluvoxamine for major depression in comparison with other anti‐depressive agents. A random effects model was used to combine information from 54 randomised controlled trials (4353 study participants) that met inclusion criteria. A further meta-analysis was conducted on 49 of these studies. Overall, no strong evidence was found to indicate that fluvoxamine was either superior or inferior to other antidepressants regarding response, remission and tolerability. However, differing side effect profiles were evident, especially regarding gastrointestinal side effects of fluvoxamine when compared to tricyclic antidepressants (TCAs).
If you have found this summary helpful, please consider making a donation. If everyone who looked at our COVID-19 resources gave us just £2 per month, it would fund Evidence Aid’s life-saving work.